NEJM-published phase 1/2 data show RASONQUE achieved a 42% response rate and 89% disease control in RAS mutant metastatic lung cancer.

Atezolizumab showed modest response rates in NSCLC patients previously treated with PD-1 inhibitors, with a suggested baseline response rate of 10% for new ICI combinations. The study's primary ...

Columvi achieved a 78.3% complete response rate and 85% overall response rate in relapsed/refractory mantle cell lymphoma patients. Cytokine release syndrome occurred in 70% of patients, with lower ...

A phase I/II trial of high-dose methotrexate (HDMTX) followed by prophylactic glucarpidase in patients with impaired renal function and central nervous system lymphoma (CNSL). SOUNDTRACK-E: A phase ...

Please provide your email address to receive an email when new articles are posted on . Furthermore, a study Kerschbaumer had previously co-authored found that placebo-treated patients on background ...

Please provide your email address to receive an email when new articles are posted on . Dostarlimab conferred clinical complete responses in all patients treated during a phase 2 trial.. Circulating ...

Role of induction chemotherapy in locally advanced oropharyngeal carcinoma in Indian population. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a ...

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, ...

Xilio Therapeutics reports 26% response rate for vilastobart and atezolizumab in metastatic MSS CRC patients, with favorable safety profile. Xilio Therapeutics has reported promising results from its ...

BARCELONA — Restarting an anti-CGRP monoclonal antibody (mAb) for migraine prevention after a gap in treatment often leads to a lower efficacy rate in the second treatment period, a new study suggests ...

SAN JUAN, Puerto Rico -- Two inhibitors of the same immune checkpoint family produced high response rates and evidence of durability in preliminary studies of advanced gynecologic cancers. Patients ...